Table 1. Clinical Features and Outcomes After Treatment.

Patient No./Sexa	Cancer Diagnosis	Treatment	Cycles to Onset of Neurological Complication	Neurological Diagnosis	Modified Rankin Scale Score	Treatment Stopped	Additional Treatments	Neurological Outcome	Modified Rankin Scale Score After Treatment
1/Male	Stage IV melanoma	Pembrolizumab	2	Severe necrotizing myopathy	5	Yes	Prednisone (80 mg daily) for 12 d, 3 sessions of plasmapheresis	Death	6
2/Male	Stage IV melanoma	Pembrolizumab	1	Myopathy	1	Yes	Methylprednisolone (1-g single dose), prednisone (100 mg daily) for 3 d and then prednisone (60 mg daily), tapering weekly over 1 mo	Improved	0
3/Male	Stage IV melanoma	Pembrolizumab	10	Axonal thoracolumbar polyradiculopathy	4	Yes	Prednisone (30 mg daily), weekly taper over 1 mo, IVIG (1 g/kg) for 2 doses	Improved	2
4/Male	Stage IV melanoma	Pembrolizumab	6	Severe demyelinating length-dependent peripheral neuropathy with axonal loss	3	Yes	Prednisone (120 mg daily), followed by slow taper over 2.5 mo	Improved	2
5/Male	Stage IV melanoma	Pembrolizumab	20	Facial diplegic variant of Guillain-Barré syndrome	2	Yes	IVIG (0.4 g/kg daily) for 5 d	Improved	1
6/Male	Stage IV peritoneal mesothelioma	Nivolumab	5	Asymmetric vasculitic neuropathy	3	Yes	Methylprednisolone (1 g intravenously daily) for 5 d, prednisone (60 mg daily), tapering over 3 wk	Improved	3
7/Male	Stage IV lung adenocarcinoma	Pembrolizumab	11	Cerebellar ataxia and dysarthria	4	Yes	None	Improved	2
8/Male	Stage IV esophageal adenocarcinoma	Pembrolizumab	3	Autoimmune retinopathy	2	No	IVIG (0.4 g/kg) 3 consecutive days every 3 wk	Improved	2
9/Female	Stage IV leiomyosarcoma	Nivolumab	3	Bilateral internuclear ophthalmoplegia	2	No	Corticosteroid (dose unknown) for 1 wk	Improved	0
10/Female	Stage IV lung adenocarcinoma	Nivolumab	14	Headache	2	No	Dexamethasone (4 mg twice daily) for 1 wk	Improved	0

Abbreviation: IVIG, intravenous immunoglobulin.

^aAges range from 31-78 years.